Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Orchestra BioMed Holdings Inc. (OBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/13/2025: OBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.58% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 168.04M USD | Price to earnings Ratio - | 1Y Target Price 15.14 |
Price to earnings Ratio - | 1Y Target Price 15.14 | ||
Volume (30-day avg) 53113 | Beta 0.59 | 52 Weeks Range 3.17 - 8.87 | Updated Date 04/1/2025 |
52 Weeks Range 3.17 - 8.87 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.6 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6591.7% |
Management Effectiveness
Return on Assets (TTM) -46.9% | Return on Equity (TTM) -120.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 96044672 | Price to Sales(TTM) 63.7 |
Enterprise Value 96044672 | Price to Sales(TTM) 63.7 | ||
Enterprise Value to Revenue 36.28 | Enterprise Value to EBITDA -1.81 | Shares Outstanding 37824600 | Shares Floating 1819270 |
Shares Outstanding 37824600 | Shares Floating 1819270 | ||
Percent Insiders 21.82 | Percent Institutions 55.5 |
Analyst Ratings
Rating 4.5 | Target Price 15.67 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Orchestra BioMed Holdings Inc.
Company Overview
History and Background
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Originally founded as Health Sciences Acquisitions Corporation 2, it completed a business combination with Orchestra BioMed, Inc. in early 2023.
Core Business Areas
- Therapeutic Medical Devices: Developing innovative therapeutic medical devices for cardiovascular diseases.
- Drug-eluting Stent Technology: Advancing drug-eluting stent (DES) technology with their Virtue Sirolimus-eluting Balloon (SEB) and BackBeat Cardiac Neuromodulation Therapy (CNT).
Leadership and Structure
Key leadership includes David Hochman (Chairman and CEO), and other experienced executives in the medical device industry. The organizational structure includes departments focused on research and development, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Virtue Sirolimus-eluting Balloon (SEB): A drug-eluting balloon for the treatment of artery disease. Currently in clinical trials, commercial success depends on regulatory approvals. Market share is currently 0% as it's pre-commercialization. Competitors include drug-eluting stents from Medtronic, Abbott, and Boston Scientific.
- BackBeat Cardiac Neuromodulation Therapy (CNT): A cardiac neuromodulation therapy designed to lower blood pressure. Market share is currently 0% as it's pre-commercialization. Competitors include pharmaceutical treatments for hypertension from companies like Novartis and Pfizer, as well as other device-based hypertension therapies from Medtronic and ReCor Medical.
Market Dynamics
Industry Overview
The cardiovascular medical device industry is a large and growing market, driven by an aging population and increasing prevalence of cardiovascular diseases. Key trends include minimally invasive procedures, drug-eluting technologies, and neuromodulation therapies.
Positioning
Orchestra BioMed is positioning itself as an innovator in the cardiovascular space with its differentiated technologies, Virtue SEB and BackBeat CNT. Its competitive advantages lie in its novel approach to drug delivery and neuromodulation.
Total Addressable Market (TAM)
The TAM for cardiovascular devices is estimated to be billions of dollars annually. Orchestra BioMed is targeting specific segments within this market, and their success depends on clinical trial outcomes and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Experienced management team
- Potential for significant market disruption
- Strategic partnership with Terumo
Weaknesses
- Reliance on clinical trial success
- Pre-commercial stage with no current revenue
- High cash burn rate
- Dependence on regulatory approvals
Opportunities
- Expanding indications for existing products
- Strategic partnerships and acquisitions
- Growing market for cardiovascular devices
- Positive clinical trial results
Threats
- Competition from established medical device companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
Competitive Landscape
Orchestra BioMed faces intense competition from established medical device companies with significantly greater resources. Its success depends on demonstrating superior efficacy and safety in clinical trials.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable as a newly public company. Focus is on development of novel products.
Future Projections: Future growth is dependent on clinical trial outcomes and regulatory approvals for Virtue SEB and BackBeat CNT. Analyst estimates will vary widely depending on these factors.
Recent Initiatives: Recent initiatives include advancing clinical trials for Virtue SEB and BackBeat CNT, securing regulatory approvals, and expanding strategic partnerships.
Summary
Orchestra BioMed is a high-risk, high-reward biomedical company focused on innovative cardiovascular therapies. Its success hinges on positive clinical trial results and regulatory approvals. The company faces significant competition but has the potential to disrupt the market with its novel technologies. Investors should be aware of the inherent uncertainties associated with early-stage medical device companies.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
CRMD
CorMedix Inc
CRMD
CorMedix Inc
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- Orchestra BioMed Holdings Inc. SEC Filings
- Industry reports on cardiovascular medical devices
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data are estimates and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Orchestra BioMed Holdings Inc.
Exchange NASDAQ | Headquaters New Hope, PA, United States | ||
IPO Launch date 2020-08-04 | Founder, Chairman of the Board of Directors & CEO Mr. David P. Hochman | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://orchestrabiomed.com |
Full time employees - | Website https://orchestrabiomed.com | ||
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.